AusBiotech

Amplia Therapeutics has used one of the world’s largest oncology stages to sharpen its case for narmafotinib, presenting mature data from its ACCENT trial that suggest the drug could meaningfully shift outcomes in one of the most difficult-to-treat cancers.

The company has been examining in greater detail how often the treatment may need to be administered, with a focus on identifying an optimal dosing regimen as it prepares the next stage of clinical development and regulatory engagement.

The expansion follows fresh preliminary data from a new cohort of six patients with squamous cell carcinoma, which continued to reinforce a favourable safety profile alongside early signs of efficacy.

The trial, known as R327 G301, is progressing across five sites in Indonesia, with patient dosing ongoing and an interim analysis planned once 155 patients have been completed.

Trajan Group Holdings has announced the appointment of long-time executive Simon Billingham as Interim Chief Financial Officer and Interim Joint Company Secretary following the departure of Alister Hodges.

The Melbourne-based biotechnology company confirmed that a recent Type C meeting with the regulator received positive feedback on both the proposed phase 1 trial design and the broader clinical strategy for DEP HER2, a dendrimer-based radioligand therapy for difficult-to-treat cancers.

AdAlta has taken a step toward addressing one of the most persistent constraints in advanced cancer treatment, signing a memorandum of understanding with Oribiotech and Cell Therapies to deploy next-generation automated manufacturing technology across its pipeline and the broader Asia Pacific region.

Atmo Biosciences has moved to strengthen its United States commercial push, appointing seasoned medtech executive Martin Reid as Senior Vice President, Sales, as the company looks to build on early momentum following regulatory clearance and initial market entry.

Immuron has reported another quarter of steady sales expansion, underpinned by continued demand for its flagship product Travelan, as the company builds momentum across key international markets.

Patrys has announced it has secured commitments to raise approximately $3.2 million through a share placement that drew strong backing from both new and existing investors.

Alterity Therapeutics has moved to deepen its leadership bench at a critical moment in its development, appointing veteran pharmaceutical executive Ann Cunningham to its Board of Directors.

The initiative marks a significant shift for the company, introducing a dual revenue model that combines its established treatment programs with a new stream of sponsor-funded services built on its existing clinical infrastructure.